primary human lung smooth muscle cells  (ATCC)

Journal: Cell Death Discovery

Article Title: Trifluoperazine causes mast cell apoptosis through a secretory granule-mediated pathway

doi: 10.1038/s41420-026-03122-x

Figure Lengend Snippet: A Human lung smooth muscle cells (HLSMCs), lung fibroblasts (HLFs), and small airway epithelial cells (HSAECs) were treated with TFP at the indicated concentrations for 24 h. Human peripheral blood eosinophils and neutrophils were treated with TFP for 2 h. Cell viability was assessed by staining the cells with Annexin V (AnnV) and DRAQ7. Viable cells, AnnV − DRAQ7 − ; apoptotic cells, AnnV + DRAQ7 − ; necrotic/late apoptotic cells, AnnV + DRAQ7 + . HSAECs, n = 6 from three independent experiments; HLSMCs, eosinophils, neutrophils, n = 4 from four independent experiments; HLFs, n = 3 from one individual experiment representative of three independent experiments (One-way ANOVA for HLSMCs, HLFs; Kruskal-Wallis for HSAECs; Friedman test for eosinophils, neutrophils). B – C Bone marrow-derived MCs (BMMCs) and peritoneal cell-derived MCs (PCMCs) treated under the same conditions as in ( A ) for 24 h. BMMCs, n = 5 from two independent experiments; PCMCs, n = 3 from one individual experiment representative of three independent experiments (One-way ANOVA). Untreated (control) cells were used for statistical comparisons to all other groups in all figures. The bar charts show mean values + SEM or median + interquartile range. * P < 0.05; ** P < 0 .01; **** P < 0.0001. D Effect of TFP on DNA degradation. MCs were preincubated with bafilomycin A1 (Baf A1) (20 nM) for 2 h followed by treatment with TFP (10 μΜ) for 2 h. DNA was extracted from MCs and fragmentation was assessed by agarose gel electrophoresis. St standard marker.

Article Snippet: Primary human lung fibroblasts (HLFs) (PCS-201-013) and primary human lung smooth muscle cells (HLSMCs)(PCS-130-010) were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured following the manufacturer’s instructions.

Techniques: Staining, Derivative Assay, Control, Agarose Gel Electrophoresis, Marker

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Cellular viability of human astrocyte cells (( A ) 24 h, ( B ) 48 h) and lung smooth muscle cells (( C ) 24 h, ( D ) 48 h) after incubation with naked pND1 and the 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 nanocomplexes formulated at N/P ratio of 5 (pND1 = 1 µg). Non-transfected cells were used as a positive control (Control (+)) and cells treated with ethanol were used as a negative control (Control (−)). Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0,05; **** p ˂ 0.0001).

Article Snippet: Human astrocyte cell line (HA1800), lung smooth muscle cells, normal, human (PCS-130-010), and human embryonic kidney (HEK293T) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Incubation, Transfection, Positive Control, Control, Negative Control, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of FITC fluorescence intensity ((a.u)/µg Protein) in the lysosomes, cytosol, and mitochondria of human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 24 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 systems. All complexes were formulated with an N/P ratio = 5 (pND1 = 1 µg). Untreated cells and naked pND1 stained with FITC were used as controls. Data were analyzed by two-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0.05; ** p ˂ 0.01; *** p ˂ 0.001; **** p ˂ 0.0001).

Article Snippet: Human astrocyte cell line (HA1800), lung smooth muscle cells, normal, human (PCS-130-010), and human embryonic kidney (HEK293T) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Fluorescence, Transfection, Staining, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of ND1 protein levels (ng/mL) in human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 48 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1), and MTS–(KH) 9 /pND1 systems (pND1 = 1 µg for all). All complexes were formulated with an N/P ratio = 5. Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison tests (** p = 0.0041 ( A ) and 0.0015 ( B ),**** p ˂ 0.0001).

Article Snippet: Human astrocyte cell line (HA1800), lung smooth muscle cells, normal, human (PCS-130-010), and human embryonic kidney (HEK293T) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Transfection, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Cellular viability of human astrocyte cells (( A ) 24 h, ( B ) 48 h) and lung smooth muscle cells (( C ) 24 h, ( D ) 48 h) after incubation with naked pND1 and the 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 nanocomplexes formulated at N/P ratio of 5 (pND1 = 1 µg). Non-transfected cells were used as a positive control (Control (+)) and cells treated with ethanol were used as a negative control (Control (−)). Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0,05; **** p ˂ 0.0001).

Article Snippet: Primary lung smooth muscle cells were maintained in vascular cell basal medium (ATCC, PCS-100-030) supplemented with 5% heat-inactivated FBS, 5% L-glutamine, 0.5 mL penicillin–streptomycin–amphotericin B solution (penicillin 10 units/mL, streptomycin 10 μg/mL and amphotericin B 25 ng/mL), 5 ng/mL of basic-fibroblasts growth factor (b-FGF), 5 ng/mL epidermal growth factor (EGF), 50 μg/mL of ascorbic acid, and 10 ng/mL of insulin.

Techniques: Incubation, Transfection, Positive Control, Control, Negative Control, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of FITC fluorescence intensity ((a.u)/µg Protein) in the lysosomes, cytosol, and mitochondria of human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 24 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 systems. All complexes were formulated with an N/P ratio = 5 (pND1 = 1 µg). Untreated cells and naked pND1 stained with FITC were used as controls. Data were analyzed by two-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0.05; ** p ˂ 0.01; *** p ˂ 0.001; **** p ˂ 0.0001).

Article Snippet: Primary lung smooth muscle cells were maintained in vascular cell basal medium (ATCC, PCS-100-030) supplemented with 5% heat-inactivated FBS, 5% L-glutamine, 0.5 mL penicillin–streptomycin–amphotericin B solution (penicillin 10 units/mL, streptomycin 10 μg/mL and amphotericin B 25 ng/mL), 5 ng/mL of basic-fibroblasts growth factor (b-FGF), 5 ng/mL epidermal growth factor (EGF), 50 μg/mL of ascorbic acid, and 10 ng/mL of insulin.

Techniques: Fluorescence, Transfection, Staining, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of ND1 protein levels (ng/mL) in human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 48 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1), and MTS–(KH) 9 /pND1 systems (pND1 = 1 µg for all). All complexes were formulated with an N/P ratio = 5. Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison tests (** p = 0.0041 ( A ) and 0.0015 ( B ),**** p ˂ 0.0001).

Article Snippet: Primary lung smooth muscle cells were maintained in vascular cell basal medium (ATCC, PCS-100-030) supplemented with 5% heat-inactivated FBS, 5% L-glutamine, 0.5 mL penicillin–streptomycin–amphotericin B solution (penicillin 10 units/mL, streptomycin 10 μg/mL and amphotericin B 25 ng/mL), 5 ng/mL of basic-fibroblasts growth factor (b-FGF), 5 ng/mL epidermal growth factor (EGF), 50 μg/mL of ascorbic acid, and 10 ng/mL of insulin.

Techniques: Transfection, Comparison